Sign In
Buy RNA
$11.35
-0.110 (-0.96%)
At Close: Jul 31, 2026
Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday
10:15am, Wednesday, 12'th Jun 2024
U.S. stocks were higher, with the Nasdaq Composite gaining over 250 points on Wednesday.
2 Potentially High-Reward Growth Stocks to Buy Right Now
08:45am, Wednesday, 29'th May 2024
Growth stocks have been the U.S. market's primary value driver since 2008. Biotechnology equities, however, have been in a wilderness period since the central bank ramped up interest rates.
Dip Then Rip? 3 Nasdaq Stocks to Buy Before the Rebound
06:00am, Thursday, 23'rd May 2024
Momentum trading is one of my favorite strategies. Legendary trader Mark Minervini, who won the U.S. investing championship in 1997 and 2021, used momentum trading strategies to win.
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 21'st May 2024
SAN DIEGO , May 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C
Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline
11:23am, Sunday, 19'th May 2024
Avidity Biosciences specializes in targeted RNA therapeutics using its AOC platform. Their most advanced drug candidate, del-desiran, shows promising results in clinical trials for myotonic DM1. The c
Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors
09:00am, Wednesday, 15'th May 2024
SAN DIEGO , May 15, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Co
Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
04:05pm, Thursday, 09'th May 2024
Initiation of global Phase 3 HARBOR™ trial for del-desiran (AOC 1001) in DM1 on track for this quarter Avidity to report FSHD data from FORTITUDE™ trial this quarter and DMD data from EXPLORE4
Avidity Biosciences to Participate in Upcoming Investor Conference
04:05pm, Wednesday, 08'th May 2024
SAN DIEGO , May 8, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Co
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 22'nd Apr 2024
SAN DIEGO , April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide
Avidity Biosciences to Participate in Upcoming Investor Conferences
09:00am, Wednesday, 27'th Mar 2024
SAN DIEGO , March 27, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 21'st Mar 2024
SAN DIEGO , March 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide
Dyne: H2 2024 Muscle Disease Data Could Boost Value
02:48pm, Tuesday, 05'th Mar 2024
Dyne: H2 2024 Muscle Disease Data Could Boost Value
Top 2% Biotech Avidity Collapses Despite 'Positive' Results In Treating Muscular Dystrophy
11:35am, Monday, 04'th Mar 2024
Top-notch biotech stock Avidity collapsed Monday despite unveiling "positive" midstage test results for its muscular dystrophy treatment.
Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch
01:39pm, Thursday, 29'th Feb 2024
Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch
Avidity Biosciences Honors Rare Disease Day®
12:00pm, Thursday, 29'th Feb 2024
SAN DIEGO , Feb. 29, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C
